Optical method for the detection of Alzheimer's disease using curcumin

Patent metadata

Field	Value
Publication number	US-10512699-B2
Application number	US-201715798612-A
Country	US
Kind code	B2
Filing date	Oct 31, 2017
Priority date	Sep 18, 2008
Publication date	Dec 24, 2019
Grant date	Dec 24, 2019

Abstract

The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively.

First claim

What is claimed is:

1. A method for diagnosing Alzheimer's disease in vivo in a human subject, comprising systemically administering curcumin to the subject for staining retinal Aβ plaques; imaging the subject's retina with an optical imaging system suitable for visualizing retinal Aβ plaques of from 1 μm to 10 μm; examining the images for stained retinal Aβ plaques of from 1 μm to 10 μm; and diagnosing the subject as having Alzheimer's disease if stained retinal Aβ plaques of from 1 μm to 10 μm are present.

2. The method of claim 1 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL), inner plexiform layer (IPL) and inner nuclear layer (INL) of the subject's retina.

3. The method of claim 1 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL) of the subject's retina.

4. The method of claim 1 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

5. The method of claim 1 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

6. A method for diagnosing Alzheimer's disease in vivo in a human subject, comprising systemically administering curcumin to the subject for staining retinal Aβ plaques; imaging the subject's retina with an optical imaging system suitable for visualizing retinal Aβ plaques of more than 5 μm; examining the image for stained retinal Aβ plaques of more than 5 μm; and diagnosing the subject as having Alzheimer's disease if stained retinal Aβ plaques of more than 5 μm are present.

7. The method of claim 6 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL), inner plexiform layer (IPL) and inner nuclear layer (INL) of the subject's retina.

8. The method of claim 6 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL) of the subject's retina.

9. The method of claim 6 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

10. The method of claim 6 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

11. A method for identifying Aβ plaques in a human subject's retina in vivo, comprising systemically administering curcumin to the subject for staining retinal Aβ plaques; imaging the subject's retina with an optical imaging system suitable for visualizing retinal Aβ plaques of from 1 μm to 10 μm; and examining the image for stained retinal Aβ plaques of from 1 μm to 10 μm.

12. The method of claim 11 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL), inner plexiform layer (IPL) and inner nuclear layer (INL) of the subject's retina.

13. The method of claim 11 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL) of the subject's retina.

14. The method of claim 11 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

15. The method of claim 11 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

16. A method for identifying Aβ plaques in a human subject's retina in vivo, comprising systemically administering curcumin to the subject for staining retinal Aβ plaques; imaging the subject's retina with an optical imaging system suitable for visualizing retinal Aβ plaques of more than 5 μm; and examining the image for stained retinal Aβ plaques of more than 5 μm.

17. The method of claim 16 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL), inner plexiform layer (IPL) and inner nuclear layer (INL) of the subject's retina.

18. The method of claim 16 , wherein stained retinal Aβ plaques are present in the ganglion cell layer (GCL) of the subject's retina.

19. The method of claim 16 , wherein the optical imaging system is selected from the group consisting of a spectrometer, a fluorescence microscope, a stereomicroscope, a mercury arc lamp, a variable wavelength light source, a xenon arc lamp, a CCD gated camera, a color digital camera, an acoustic-optic tunable filter-based spectral image acquisition system, adaptive optics, imaging software, and combinations thereof.

20. The method of claim 16 , wherein the amount of curcumin administered is less than 12.0 grams and greater than 7.5 mg.

Assignees

• Cedars Sinai Medical Center
• Yeda Res & Dev

Inventors

• Koronyo Yosef
• Koronyo Maya
• Black Keith
• Schwartz Michal
• Farkas Daniel L

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/12

  for cataracts · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title